Nearly all adults with Down syndrome will develop indications of Alzheimer’s Disease (AD) by as early as 40 years old, including amyloid plaque on the brain. Lecanemab is a drug designed to target and remove amyloid plaque, and recently approved by the U.S. Food and Drug Administration. However, people with Down...